$DARE
Dare Bioscience, Inc. Stock $dare

$dare Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000140191419000048 Filed on May 14, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.470M	$1.390M	$1.400M
YoY Change	4.26%	-0.71%	600.0%
% of Gross Profit
Research & Development	$2.513M	$1.693M	$1.087M
YoY Change	13.3%	55.84%	-76.64%
% of Gross Profit
Depreciation & Amortization	$0.00	$1.150K	$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses	$3.982M	$3.083M	$7.677M
YoY Change	9.87%	-59.84%	13.94%
Operating Profit	-$3.982M	-$3.083M	-$7.677M
YoY Change	9.87%	-59.84%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$30.00K	$31.23K	$11.74K
YoY Change	-29.62%	165.93%	-101.48%
Pretax Income	-$3.950M	-$3.050M	-$7.670M
YoY Change	10.34%	-60.23%	3095.83%
Income Tax
% Of Pretax Income
Net Earnings	-$3.952M	-$3.052M	-$7.666M
YoY Change	10.34%	-60.19%	20.93%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$245.2K	-$267.1K	-$883.6K
COMMON SHARES
Basic Shares Outstanding	16.68M shares	11.42M shares	8.685M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.630M	$3.510M	$15.63M
YoY Change	-54.78%	-77.54%	29.93%
Cash & Equivalents	$5.600M	$3.500M	$15.63M
Short-Term Investments
Other Short-Term Assets	$440.0K	$590.0K	$290.0K
YoY Change	25.71%	103.45%	-88.16%
Inventory
Prepaid Expenses	$438.0K	$588.5K	$290.9K
Receivables
Other Receivables	$493.0K	$166.7K
Total Short-Term Assets	$6.562M	$4.260M	$15.94M
YoY Change	-48.82%	-73.28%	2.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.081K	$8.245K
YoY Change	-10.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$692.3K	$751.3K	$690.0K
YoY Change	4.89%	8.89%	200.0%
Total Long-Term Assets	$699.4K	$759.6K	$685.2K
YoY Change	5.97%	10.86%	99.19%
TOTAL ASSETS
Total Short-Term Assets	$6.562M	$4.260M	$15.94M
Total Long-Term Assets	$699.4K	$759.6K	$685.2K
Total Assets	$7.261M	$5.020M	$16.63M
YoY Change	-46.14%	-69.81%	4.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$630.0K	$330.0K	$810.0K
YoY Change	-50.39%	-59.26%	25.78%
Accrued Expenses	$1.342M	$690.8K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.974M	$1.016M	$807.6K
YoY Change	55.43%	25.86%	-87.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$203.9K	$223.0K	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$203.9K	$223.0K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.974M	$1.016M	$807.6K
Total Long-Term Liabilities	$203.9K	$223.0K	$0.00
Total Liabilities	$2.178M	$1.239M	$810.5K
YoY Change	71.49%	52.93%	-90.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.80M	-$32.02M	-$19.90M
YoY Change		60.94%	-90.39%
Common Stock	$41.94M	$35.89M	$35.75M
YoY Change		0.4%	-83.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.083M	$3.780M	$15.82M
YoY Change
Total Liabilities & Shareholders Equity	$7.261M	$5.020M	$16.63M
YoY Change	-46.14%	-69.82%	4.25%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$3.952M	-$3.052M	-$7.666M
YoY Change	10.34%	-60.19%	20.93%
Depreciation, Depletion And Amortization	$0.00	$1.150K	$0.00
YoY Change			-100.0%
Cash From Operating Activities	-$3.020M	-$3.308M	-$2.119M
YoY Change	12.27%	56.14%	4137.77%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change	-100.0%
Cash From Investing Activities	$0.00
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$5.200M		$10.10M
YoY Change			16190.32%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.150M	$0.00	$10.20M
YoY Change		-100.0%	10097.81%
NET CHANGE
Cash From Operating Activities	-3.020M	-$3.308M	-$2.119M
Cash From Investing Activities	0.000
Cash From Financing Activities	5.150M	$0.00	$10.20M
Net Change In Cash	2.130M	-$3.301M	$8.065M
YoY Change	-167.62%	-140.93%	16030.36%
FREE CASH FLOW
Cash From Operating Activities	-$3.020M	-$3.308M	-$2.119M
Capital Expenditures	$0.00
Free Cash Flow	-$3.020M
YoY Change	12.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dare	Adjustments To Additional Paid In Capital Common Stock And Warrants Issued AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued	1037764	USD
CY2017Q3	dare	Business Combination Purchase Price Adjustment Increase In Current Assets BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets	225778	USD
CY2017Q3	dare	Business Combination Purchase Price Adjustment Increase In Current Liabilities BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities	23609	USD
CY2017Q3	dare	Business Combination Reverse Merger Consideration Transferred BusinessCombinationReverseMergerConsiderationTransferred	24300000	USD
CY2017Q3	dare	Business Combination Reverse Merger Consideration Transferred BusinessCombinationReverseMergerConsiderationTransferred	24279000	USD
CY2017Q3	dare	Business Combination Reverse Merger Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable	20625000	USD
CY2017Q3	dare	Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	9918000	USD
CY2017Q3	dare	Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	9900000	USD
CY2017Q3	dare	Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Current Assets BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets	1915000	USD
CY2017Q3	dare	Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	233000	USD
CY2017Q3	dare	Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	11600000	USD
CY2017Q3	dare	Business Combination Reverse Merger Unamortized Fair Value Of Stock Options BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions	3654000	USD
CY2017Q3	dare	Business Combination Reverse Merger Unamortized Fair Value Of Stock Options BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions	3700000	USD
CY2018Q1	dare	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	1100000	USD
CY2018Q1	dare	Increase Decrease In Other Non Current Assets And Deferred Charges IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges	-37131	USD
CY2019Q1	dare	Increase Decrease In Other Non Current Assets And Deferred Charges IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges	-55233	USD
CY2018Q1	dare	License Fee LicenseFee	100000	USD
CY2019Q1	dare	License Fee LicenseFee	112500	USD
CY2018Q1	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	10197813	USD
CY2019Q1	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2019Q1	dare	Non Cash Lease Expense NonCashLeaseExpense	10130	USD
CY2018Q1	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
CY2019Q1	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
CY2018Q3	dare	Percentage Of Increase In Annual Base Rent PercentageOfIncreaseInAnnualBaseRent	0.04
CY2019Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	35889940	USD
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	dei	Trading Symbol TradingSymbol	DARE
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	459705	USD
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	Dare Bioscience, Inc.
CY2019Q1	dare	Reimbursement Of Grant Expenses Receivable ReimbursementOfGrantExpensesReceivable	161007	USD
CY2018Q1	dare	Research And Development Milestone Payment ResearchAndDevelopmentMilestonePayment	75000	USD
CY2019Q1	dare	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.000
CY2019Q1	dare	Stock Option Modification Approval Date StockOptionModificationApprovalDate	2017-03-19
CY2019Q1	dare	Weighted Average Amortization Period WeightedAverageAmortizationPeriod	P3Y3M18D
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001401914
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16683411	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	325618	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	631351	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	690829	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-96728	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-89107	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	35791972	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3300863	USD
CY2019Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3750833	shares
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15625026	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6805889	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3505026	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8065180	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3505026	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7559846	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9124	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	97968	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4294398	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5941193	shares
CY2018Q4	us-gaap	Assets Assets	7827387	USD
CY2019Q1	us-gaap	Assets Assets	5019855	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	7240023	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	4260263	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6805889	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3500000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11422161	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11422161	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11422161	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11422161	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1143	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	1143	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7679363	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3044219	USD
CY2019Q1	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	1343624	USD
CY2018Q1	us-gaap	Depreciation Depreciation	0	USD
CY2019Q1	us-gaap	Depreciation Depreciation	1150	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-13746	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	7621	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1303189	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1277180	USD
CY2017Q4	us-gaap	Goodwill Goodwill	5200000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	12700000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	12679000	USD
CY2018Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P1Y
CY2018Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P37M
CY2018Q3	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	8873	USD
CY2017Q3	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	12900000	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	7500000	USD
CY2018Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5187519	USD
CY2018Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5200000	USD
CY2019Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q3	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-202169	USD
CY2018Q2	us-gaap	Grants Receivable GrantsReceivable	1900000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-40340	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-134087	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-118707	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	59478	USD
CY2018Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-193495	USD
CY2019Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2496	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-9711	USD
CY2018Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-255318	USD
CY2019Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	135676	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-20694	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	201129	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	262488	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	81950	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	67595	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	112943	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	39449	USD
CY2018Q4	us-gaap	Liabilities Liabilities	1100767	USD
CY2019Q1	us-gaap	Liabilities Liabilities	1239486	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7827387	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5019855	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1091056	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1016447	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10197813	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2118887	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3308484	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3300000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-7665617	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3051840	USD
CY2018Q3	us-gaap	Net Rentable Area NetRentableArea	3169	sqft
CY2019Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	7677361	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	3083071	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7677361	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3083071	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	27038	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	223039	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	241000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	83751	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139288	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	26620	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	212909	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	232000	USD
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q1	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	224665	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1086653	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	577968	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	751347	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-13746	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7621	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9711	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	223039	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11744	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31231	USD
CY2018Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	31037	USD
CY2019Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	166713	USD
CY2019Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	237403	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	403097	USD
CY2019Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	588524	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-7665617	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-3051840	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9396	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8245	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1693391	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28969767	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32000000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32021607	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	231698	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9124	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	97968	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.20
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0270
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	650151	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	25.97
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	70	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	8360	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	563000	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.72
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.40
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	59.48
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.81
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.76
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1635790	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2190360	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.08
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2018Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.70
CY2018Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5000000	shares
CY2018Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	375000	shares
CY2019Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares
CY2019Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9160048	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	13292783	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	15820356	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	6726620	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	3780369	USD
CY2018Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8684550	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11422161	shares

Files In Submission

Name	View Source	Status
0001401914-19-000048-index-headers.html	Edgar Link	pending
0001401914-19-000048-index.html	Edgar Link	pending
0001401914-19-000048.txt	Edgar Link	pending
0001401914-19-000048-xbrl.zip	Edgar Link	pending
dare-03312019x10q.htm	Edgar Link	pending
dare-20190331.xml	Edgar Link	completed
dare-20190331.xsd	Edgar Link	pending
dare-20190331_cal.xml	Edgar Link	unprocessable
dare-20190331_def.xml	Edgar Link	unprocessable
dare-20190331_lab.xml	Edgar Link	unprocessable
dare-20190331_pre.xml	Edgar Link	unprocessable
darecovera03.jpg	Edgar Link	pending
exhibit311.htm	Edgar Link	pending
exhibit312.htm	Edgar Link	pending
exhibit321.htm	Edgar Link	pending
exhibit322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DARE
Dare Bioscience, Inc. Stock $dare

2019 Q2 Form 10-Q Financial Statement

#000140191419000048 Filed on May 14, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE Dare Bioscience, Inc. Stock $dare

2019 Q2 Form 10-Q Financial Statement

#000140191419000048 Filed on May 14, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE
Dare Bioscience, Inc. Stock $dare